Effect of Nervus Cutaneous Femoris Lateralis-Blockade on Moderate Pain Responders After Total Hip Arthroplasty
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The patients will be included the 1. or 2. day after surgery. All THA patients will be
screened. Those reporting VAS > 40 during active 30 degrees hip flexion will be asked to
participate.
Included patients will receive 2xNCFL (singleshot) first placebo (8 ml saline) and then
ropivacaine (8 ml ropivacaine 7,5mg/ml) or the other way around (randomized). There will be
45 minutes between the two blockades. The blockades will be ultrasound guided.